Bernstein has initiated coverage on BridgeBio Pharma Inc (BBIO) with an Outperform rating as of December 10, 2025. The current share price stands at $73.21.
BridgeBio Pharma, headquartered in Palo Alto, California, focuses on developing transformative medicines for patients with Mendelian diseases. The biotechnology firm has a robust pipeline, including treatments such as Attruby for transthyretin-mediated amyloidosis and BBP-418 for Limb Girdle Muscular Dystrophy Type 2I.
As of November 8, 2025, BridgeBio's market capitalization is $12.0 billion, with a trailing twelve months (TTM) earnings per share (EPS) of -4.19. Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of -0.59 and revenue of $195.8 million.
Analyst consensus for BridgeBio indicates 7 Strong Buy, 16 Buy, and 2 Hold ratings, reflecting a general positive outlook among analysts. Recent actions include Bernstein's initiation and several firms maintaining their ratings, underscoring the ongoing interest in the company's potential.